BNP Paribas Upgrades GlaxoSmithKline (GSK) to “Outperform”

BNP Paribas upgraded shares of GlaxoSmithKline (NYSE:GSK) from a neutral rating to an outperform rating in a research report released on Wednesday, Marketbeat reports.

A number of other brokerages have also weighed in on GSK. Kepler Capital Markets upgraded shares of GlaxoSmithKline from a reduce rating to a hold rating in a report on Friday, February 9th. Zacks Investment Research lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a report on Wednesday, January 10th. Cowen restated a hold rating and issued a $40.00 price objective on shares of GlaxoSmithKline in a report on Thursday, February 15th. ValuEngine lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a report on Friday, February 2nd. Finally, JPMorgan Chase restated a neutral rating on shares of GlaxoSmithKline in a report on Thursday, January 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $39.96.

How to Become a New Pot Stock Millionaire

Shares of NYSE GSK opened at $39.93 on Wednesday. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53. The company has a market capitalization of $98,830.24, a P/E ratio of 13.86, a PEG ratio of 2.22 and a beta of 0.84. The company has a quick ratio of 0.39, a current ratio of 0.60 and a debt-to-equity ratio of 4.09.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The company had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion. sell-side analysts expect that GlaxoSmithKline will post 2.94 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be paid a dividend of $0.633 per share. The ex-dividend date is Thursday, February 22nd. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 dividend on an annualized basis and a yield of 6.34%. GlaxoSmithKline’s payout ratio is currently 87.85%.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC raised its stake in GlaxoSmithKline by 2.4% during the 4th quarter. Renaissance Technologies LLC now owns 9,668,300 shares of the pharmaceutical company’s stock valued at $342,935,000 after buying an additional 230,600 shares during the last quarter. Two Sigma Advisers LP raised its stake in GlaxoSmithKline by 55.5% during the 4th quarter. Two Sigma Advisers LP now owns 5,074,642 shares of the pharmaceutical company’s stock valued at $179,998,000 after buying an additional 1,811,400 shares during the last quarter. NWQ Investment Management Company LLC raised its stake in GlaxoSmithKline by 9.4% during the 3rd quarter. NWQ Investment Management Company LLC now owns 2,728,458 shares of the pharmaceutical company’s stock valued at $110,775,000 after buying an additional 233,689 shares during the last quarter. Two Sigma Investments LP raised its stake in GlaxoSmithKline by 23.7% during the 4th quarter. Two Sigma Investments LP now owns 2,388,168 shares of the pharmaceutical company’s stock valued at $84,708,000 after buying an additional 457,276 shares during the last quarter. Finally, Brandes Investment Partners LP raised its stake in GlaxoSmithKline by 6.1% during the 4th quarter. Brandes Investment Partners LP now owns 2,262,946 shares of the pharmaceutical company’s stock valued at $80,267,000 after buying an additional 130,182 shares during the last quarter. Institutional investors and hedge funds own 10.96% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “BNP Paribas Upgrades GlaxoSmithKline (GSK) to “Outperform”” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/bnp-paribas-upgrades-glaxosmithkline-gsk-to-outperform.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply